Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This will be a phase I study of carfilzomib in combination with vorinostat in patients with
relapsed/refractory B-cell lymphomas. Combination therapy with proteosome inhibitor PR-171
and HDAC inhibitors is highly synergistic in primary DLBCL cells, and both classes of drugs
can also synergize powerfully to induce cell death in bortezomib-resistant cells. The purpose
of this study is to see if vorinostat can combine with carfilzomib and to safely find the
recommended phase II dose.